NYSE:JNJ

Johnson & Johnson Competitors

$164.76
-0.20 (-0.12 %)
(As of 06/14/2021 02:28 PM ET)
Add
Compare
Today's Range
$163.90
$164.90
50-Day Range
$159.48
$171.07
52-Week Range
$133.65
$173.65
Volume189,104 shs
Average Volume7.73 million shs
Market Capitalization$433.88 billion
P/E Ratio29.11
Dividend Yield2.57%
Beta0.71

Johnson & Johnson (NYSE:JNJ) Vs. UNH, PFE, LLY, NVS, ABBV, and NVO

Should you be buying JNJ stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Johnson & Johnson, including UnitedHealth Group (UNH), Pfizer (PFE), Eli Lilly and (LLY), Novartis (NVS), AbbVie (ABBV), and Novo Nordisk A/S (NVO).

Johnson & Johnson (NYSE:JNJ) and UnitedHealth Group (NYSE:UNH) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider & Institutional Ownership

66.7% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 86.2% of UnitedHealth Group shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.8% of UnitedHealth Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Johnson & Johnson and UnitedHealth Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.58 billion5.24$14.71 billion$8.0320.46
UnitedHealth Group$257.14 billion1.45$15.40 billion$16.8823.46

UnitedHealth Group has higher revenue and earnings than Johnson & Johnson. Johnson & Johnson is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.3%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. UnitedHealth Group pays out 29.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and UnitedHealth Group has raised its dividend for 11 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Johnson & Johnson and UnitedHealth Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson021002.83
UnitedHealth Group031612.90

Johnson & Johnson currently has a consensus price target of $185.70, suggesting a potential upside of 12.98%. UnitedHealth Group has a consensus price target of $425.1364, suggesting a potential upside of 7.32%. Given Johnson & Johnson's higher probable upside, equities research analysts clearly believe Johnson & Johnson is more favorable than UnitedHealth Group.

Profitability

This table compares Johnson & Johnson and UnitedHealth Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson17.95%34.62%13.13%
UnitedHealth Group6.42%26.04%9.02%

Risk and Volatility

Johnson & Johnson has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, UnitedHealth Group has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

UnitedHealth Group beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider and Institutional Ownership

66.7% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 64.2% of Pfizer shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.9%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Pfizer pays out 70.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Profitability

This table compares Johnson & Johnson and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson17.95%34.62%13.13%
Pfizer22.09%24.55%9.61%

Valuation & Earnings

This table compares Johnson & Johnson and Pfizer's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.58 billion5.24$14.71 billion$8.0320.46
Pfizer$41.91 billion5.28$9.62 billion$2.2217.82

Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Johnson & Johnson has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Johnson & Johnson and Pfizer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson021002.83
Pfizer011202.15

Johnson & Johnson currently has a consensus target price of $185.70, suggesting a potential upside of 12.98%. Pfizer has a consensus target price of $39.9286, suggesting a potential upside of 0.93%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts plainly believe Johnson & Johnson is more favorable than Pfizer.

Summary

Johnson & Johnson beats Pfizer on 13 of the 17 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Insider and Institutional Ownership

66.7% of Johnson & Johnson shares are held by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.5%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Eli Lilly and has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Johnson & Johnson and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson17.95%34.62%13.13%
Eli Lilly and23.91%132.28%16.36%

Earnings and Valuation

This table compares Johnson & Johnson and Eli Lilly and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.58 billion5.24$14.71 billion$8.0320.46
Eli Lilly and$24.54 billion8.81$6.19 billion$7.9328.42

Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Johnson & Johnson has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Johnson & Johnson and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson021002.83
Eli Lilly and021112.93

Johnson & Johnson currently has a consensus price target of $185.70, suggesting a potential upside of 12.98%. Eli Lilly and has a consensus price target of $207.4286, suggesting a potential downside of 8.03%. Given Johnson & Johnson's higher possible upside, research analysts plainly believe Johnson & Johnson is more favorable than Eli Lilly and.

Summary

Eli Lilly and beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Johnson & Johnson and Novartis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson021002.83
Novartis23702.42

Johnson & Johnson currently has a consensus price target of $185.70, suggesting a potential upside of 12.98%. Novartis has a consensus price target of $108.50, suggesting a potential upside of 16.28%. Given Novartis' higher possible upside, analysts plainly believe Novartis is more favorable than Johnson & Johnson.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.2%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Novartis has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

66.7% of Johnson & Johnson shares are held by institutional investors. Comparatively, 10.1% of Novartis shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Johnson & Johnson has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Earnings and Valuation

This table compares Johnson & Johnson and Novartis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.58 billion5.24$14.71 billion$8.0320.46
Novartis$48.66 billion4.39$8.07 billion$5.7516.22

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Johnson & Johnson and Novartis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson17.95%34.62%13.13%
Novartis16.31%24.15%10.27%

Summary

Johnson & Johnson beats Novartis on 15 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for AbbVie and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie111102.77
Johnson & Johnson021002.83

AbbVie presently has a consensus price target of $119.4615, indicating a potential upside of 4.17%. Johnson & Johnson has a consensus price target of $185.70, indicating a potential upside of 12.98%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than AbbVie.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Johnson & Johnson has raised its dividend for 59 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

66.1% of AbbVie shares are owned by institutional investors. Comparatively, 66.7% of Johnson & Johnson shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

AbbVie has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares AbbVie and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$45.80 billion4.42$4.62 billion$10.5610.85
Johnson & Johnson$82.58 billion5.24$14.71 billion$8.0320.46

Johnson & Johnson has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie10.28%136.75%12.95%
Johnson & Johnson17.95%34.62%13.13%

Summary

Johnson & Johnson beats AbbVie on 10 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Novo Nordisk A/S and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novo Nordisk A/S24302.11
Johnson & Johnson021002.83

Johnson & Johnson has a consensus price target of $185.70, indicating a potential upside of 12.98%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Novo Nordisk A/S.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.6%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has raised its dividend for 1 consecutive years and Johnson & Johnson has raised its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

5.7% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 66.7% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Novo Nordisk A/S has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Novo Nordisk A/S and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$19.45 billion10.21$6.46 billion$2.7630.54
Johnson & Johnson$82.58 billion5.24$14.71 billion$8.0320.46

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Johnson & Johnson is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novo Nordisk A/S and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novo Nordisk A/S33.77%71.90%30.84%
Johnson & Johnson17.95%34.62%13.13%

Summary

Johnson & Johnson beats Novo Nordisk A/S on 11 of the 17 factors compared between the two stocks.

Ad Mining News Daily
Bullish Silver Price Forecast
High-grade Alamos silver project is the first modern exploration program in the district

Johnson & Johnson Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
UnitedHealth Group logo
UNH
UnitedHealth Group
2.4$395.95-0.5%$375.49 billion$257.14 billion22.51Dividend Increase
Pfizer logo
PFE
Pfizer
1.9$39.56-1.5%$224.75 billion$41.91 billion20.18
Eli Lilly and logo
LLY
Eli Lilly and
2.0$225.38-0.6%$214.91 billion$24.54 billion33.69Analyst Report
Insider Selling
Novartis logo
NVS
Novartis
2.0$93.28-0.6%$212.14 billion$48.66 billion26.80
AbbVie logo
ABBV
AbbVie
2.4$114.57-0.7%$203.86 billion$45.80 billion40.48
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.3$84.30-0.2%$198.86 billion$19.45 billion29.27
Abbott Laboratories logo
ABT
Abbott Laboratories
2.7$110.17-0.2%$195.29 billion$34.61 billion34.54Dividend Announcement
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.3$75.05-1.6%$193.12 billion$47.99 billion27.19
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.0$466.31-0.2%$182.82 billion$32.22 billion23.48
Medtronic logo
MDT
Medtronic
2.4$123.29-0.4%$166.86 billion$30.12 billion46.35
AstraZeneca logo
AZN
AstraZeneca
2.2$58.66-0.2%$154.25 billion$26.62 billion38.59
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
1.9$66.89-0.7%$150.36 billion$42.52 billion-24.06
Amgen logo
AMGN
Amgen
2.4$240.09-1.1%$139.48 billion$25.42 billion19.89Decrease in Short Interest
Sanofi logo
SNY
Sanofi
1.4$53.84-0.1%$135.47 billion$41.17 billion18.76
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.6$40.31-0.4%$108.11 billion$43.79 billion14.77Analyst Report
Decrease in Short Interest
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.6$868.23-0.5%$102.34 billion$4.36 billion89.51
Stryker logo
SYK
Stryker
1.9$255.30-0.2%$96.37 billion$14.35 billion69.19Increase in Short Interest
Anthem logo
ANTM
Anthem
2.2$381.91-0.5%$93.99 billion$121.87 billion20.44
Moderna logo
MRNA
Moderna
1.4$208.25-5.1%$87.87 billion$803.40 million166.60Insider Selling
Zoetis logo
ZTS
Zoetis
1.8$182.74-0.3%$86.46 billion$6.68 billion49.26
Gilead Sciences logo
GILD
Gilead Sciences
2.8$67.56-1.8%$86.25 billion$24.69 billion293.75Unusual Options Activity
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$241.30-0.6%$70.56 billion$17.12 billion42.94
HCA Healthcare logo
HCA
HCA Healthcare
2.3$206.72-2.4%$70.00 billion$51.53 billion15.45Decrease in Short Interest
Illumina logo
ILMN
Illumina
1.2$450.71-0.5%$66.16 billion$3.24 billion105.31
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$100.11-0.1%$62.16 billion$4.39 billion74.16
Boston Scientific logo
BSX
Boston Scientific
1.9$42.54-0.9%$60.97 billion$9.91 billion425.40
Biogen logo
BIIB
Biogen
1.8$406.83-2.5%$59.72 billion$13.44 billion21.34Analyst Upgrade
Analyst Revision
BioNTech logo
BNTX
BioNTech
0.9$220.26-8.3%$57.61 billion$550.91 million38.57Decrease in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$193.89-0.4%$56.11 billion$6.21 billion18.47Analyst Report
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.8$527.98-0.5%$55.99 billion$8.50 billion14.94
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.10-0.6%$54.31 billion$30.17 billion15.13
Humana logo
HUM
Humana
2.1$413.93-1.3%$54.08 billion$77.16 billion14.72
Koninklijke Philips logo
PHG
Koninklijke Philips
1.2$54.16-4.3%$51.14 billion$22.31 billion35.63Decrease in Short Interest
News Coverage
Gap Down
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$589.20-0.8%$49.84 billion$2.71 billion75.83Increase in Short Interest
Align Technology logo
ALGN
Align Technology
1.7$606.58-0.8%$48.40 billion$2.47 billion105.49
Baxter International logo
BAX
Baxter International
2.1$81.83-0.5%$41.35 billion$11.67 billion39.34
Centene logo
CNC
Centene
1.9$69.24-2.3%$41.26 billion$111.12 billion16.53
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.5$181.23-0.2%$40.15 billion$6.07 billion59.23
DexCom logo
DXCM
DexCom
2.0$405.55-1.3%$38.70 billion$1.93 billion79.52
Alcon logo
ALC
Alcon
1.5$71.01-0.8%$34.39 billion$6.83 billion-88.76
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.3$156.97-0.8%$33.20 billion$7.02 billion58.35Dividend Announcement
BeiGene logo
BGNE
BeiGene
1.0$346.08-0.2%$31.85 billion$308.87 million-25.39Analyst Report
Insider Selling
ResMed logo
RMD
ResMed
1.6$228.95-4.5%$31.81 billion$2.96 billion73.15Analyst Report
Insider Selling
McKesson logo
MCK
McKesson
2.1$191.53-2.1%$30.93 billion$238.23 billion-6.69Decrease in Short Interest
Genmab A/S logo
GMAB
Genmab A/S
1.2$44.32-1.3%$28.70 billion$1.55 billion34.09
Seagen logo
SGEN
Seagen
1.4$156.05-0.3%$28.42 billion$2.18 billion43.23
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$343.25-0.6%$25.38 billion$2.15 billion61.51
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$258.37-0.1%$25.26 billion$13.98 billion9.60
AmerisourceBergen logo
ABC
AmerisourceBergen
1.5$118.04-1.5%$24.62 billion$189.89 billion-6.41
Cerner logo
CERN
Cerner
1.8$80.14-1.4%$24.49 billion$5.51 billion30.59
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.